These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16234364)

  • 21. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
    Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
    Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
    Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
    Khong T; Spencer A
    Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
    Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
    Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
    Jia W; Yu C; Rahmani M; Krystal G; Sausville EA; Dent P; Grant S
    Blood; 2003 Sep; 102(5):1824-32. PubMed ID: 12738674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death.
    Bai L; Xu S; Chen W; Li Z; Wang X; Tang H; Lin Y
    Apoptosis; 2011 Jan; 16(1):45-54. PubMed ID: 20862547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
    Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
    Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
    Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
    Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
    Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
    Premkumar DR; Arnold B; Jane EP; Pollack IF
    Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
    Gossett DR; Bradley MS; Jin X; Lin J
    Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
    Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
    Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.